Arcellx Inc (ACLX) Price & Analysis

Compare

255 Followers

ACLX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$47.86 - $107.37

Previous CloseN/A

Volume227.93K

Average Volume (3M)563.71K

Market Cap

$4.17B

Enterprise Value$3.30B

Total Cash (Recent Filing)$543.26M

Total Debt (Recent Filing)$53.19M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Nov 17, 2025

EPS Estimate

-0.99

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.94

Shares Outstanding55,458,910

10 Day Avg. Volume463,631

30 Day Avg. Volume563,706

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue42.98

Enterprise Value/Gross Profit43.69

Enterprise Value/Ebitda-20.36

Forecast

1Y Price Target

$116.27

Price Target Upside50.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Commercial StrategyPlans are in place to launch anito-cel in 160+ treatment centers, indicating a strong commercial strategy.

Efficacy And SafetyAnito-cel achieved an excellent minimal residual disease (MRD) negative rate of 93% in the iMMagine-1 study, boosting confidence in its efficacy.

Regulatory ProgressThe company's relationship with Kite, known for regulatory expertise, supports confidence in potential FDA approval.

Bears Say

Development TimelineArcellx remains on track to launch anito-cel in mid-to-late 2026, indicating progress in their development timeline.

Market CompetitionAvoiding a Parkinsonism risk on the label would solidify anito-cel's improved competitive positioning and provide a boost to the launch.

Arcellx Inc News

3 Stocks to Buy Now, According to the Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

28d ago

CXW

ACLX

$Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma$

Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Arcellx Inc on August 8 and set a...

1M ago

ACLX

Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs

Arcellx, Inc. ( ($ACLX) ) has released its Q2 earnings. Here is a breakdown of the information Arcellx,...

1M ago

ACLX

Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Arcellx Inc and keeping the price target...

1M ago

ACLX

Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating...

1M ago

ACLX

Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating on...

1M ago

ACLX

Arcellx reports Q2 EPS (94c), consensus ($1.03)

Reports Q2 revenue $7.6M, consensus $13.9M. As of June 30, 2025, Arcellx (ACLX) had cash, cash equivalents, and...

1M ago

ACLX

These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

1M ago

ACLX

JAZZ

Arcellx’s Innovative CAR-T Therapy Study for GMG: A Potential Game-Changer

Arcellx, Inc. (($ACLX)) announced an update on their ongoing clinical study. Arcellx, Inc. is conducting a Phase 1...

2M ago

ACLX

Arcellx price target raised to $133 from $93 at Scotiabank

Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $93 and keeps an Outperform rating...

2M ago

ACLX

Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment

Arcellx, Inc. (($ACLX)) announced an update on their ongoing clinical study. Arcellx, Inc. (ACLX) is advancing its clinical...

2M ago

ACLX

Arcellx initiated with a Buy at Citi

Citi initiated coverage of Arcellx (ACLX) with a Buy rating and $110 price target The firm sees “significant...

3M ago

ACLX

Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report), retaining...

3M ago

ACLX

Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel

Arcellx (ACLX) announced new data from its Phase 2 iMMagine-1 study of anitocabtagene autoleucel, in patients with relapsed...

4M ago

ACLX

GILD

ACLX FAQ

What was Arcellx Inc’s price range in the past 12 months?

Arcellx Inc lowest stock price was $47.86 and its highest was $107.37 in the past 12 months.

What is Arcellx Inc’s market cap?

Arcellx Inc’s market cap is $4.17B.

When is Arcellx Inc’s upcoming earnings report date?

Arcellx Inc’s upcoming earnings report date is Nov 17, 2025 which is in 60 days.

How were Arcellx Inc’s earnings last quarter?

Arcellx Inc released its earnings results on Aug 07, 2025. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.065.

Is Arcellx Inc overvalued?

According to Wall Street analysts Arcellx Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcellx Inc pay dividends?

Arcellx Inc does not currently pay dividends.

What is Arcellx Inc’s EPS estimate?

Arcellx Inc’s EPS estimate is -0.99.

How many shares outstanding does Arcellx Inc have?

Arcellx Inc has 55,458,910 shares outstanding.

What happened to Arcellx Inc’s price movement after its last earnings report?

Arcellx Inc reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -0.914%.

Which hedge fund is a major shareholder of Arcellx Inc?

Currently, no hedge funds are holding shares in ACLX

Arcellx Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-42.75%

Trailing 12-Months

Asset Growth

-15.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcellx Inc

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx Inc (ACLX) Earnings & Revenues

Historic Earnings Reports

ACLX Stock 12 Month Forecast

Average Price Target

$116.27

▲(50.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","96":"$96","135":"$135","76.5":"$76.5","115.5":"$115.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$134.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$116.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$104.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,76.5,96,115.5,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.14,75.97538461538461,80.81076923076924,85.64615384615385,90.48153846153846,95.31692307692308,100.15230769230769,104.98769230769231,109.82307692307693,114.65846153846154,119.49384615384616,124.32923076923078,129.1646153846154,{"y":134,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.14,74.61153846153846,78.08307692307692,81.55461538461539,85.02615384615385,88.4976923076923,91.96923076923076,95.44076923076923,98.91230769230769,102.38384615384615,105.85538461538461,109.32692307692307,112.79846153846154,{"y":116.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.14,73.6676923076923,76.19538461538461,78.72307692307692,81.25076923076924,83.77846153846154,86.30615384615385,88.83384615384615,91.36153846153846,93.88923076923078,96.41692307692307,98.94461538461539,101.4723076923077,{"y":104,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >